Human CD19-CD22 Targeted T Cells Injection Clinical Trials

1 actively recruiting trial

Also known as: CD19-CD22 CAR-T

Pipeline

Early 1: 1

Top Sponsors

Hrain Biotechnology Co., Ltd.1

Indications

Central Nervous System Lymphoma1
Cancer1

Other1 trial

Human CD19-CD22 Targeted T Cells Injection for Refractory/Relapsed Central Nervous System Leukemia/Lymphoma Patients

Early 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.